Biomx Inc. · AMEX:PHGE
Biomx — Investor Presentation (August 2025)
27 slides from Biomx's investor presentation, August 2025
Slide 1: Corporate Presentation August 2025
Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance Corporate Presentation August 2025 NYSE American: PHGE
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT About this Presentation The information contained in this presentation has been prepared by BiomX Inc. and its subsidiaries (collectively, the “Company” or “BiomX”) and contains information pertaining to the business and operations of the Company. The information contained in t
Slide 3: Antimicrobial Resistance: Rising concerns and limited treatment options
Antimicrobial Resistance: Rising concerns and limited treatment options underscore the urgent need for novel therapies Resistance Rate of 10M 35% S. Aureus to antibiotic Methicillin1 Annual Deaths by 2050 WHO projected Antimicrobial Resistance Mortality3 Increase in Death Associated 70% with Antimic
Slide 4: Phage Therapy: A century-old solution with renewed promise
Phage Therapy: A century-old solution with renewed promise Key Advantages Self-Amplifying Targets Only Ability to Launch Active against Safe Modality, Phages Increase Harmful Bacteria Penetrates and Straight into Antibiotic Inert to Human Efficacy of Each – No Disruption Disrupts Biofilm Early/Mid C
Slide 5: Phage Therapy Momentum: Growing clinical data signal a pivotal moment
Phage Therapy Momentum: Growing clinical data signal a pivotal moment ahead1 March 2025: BiomX positive P2 data Nov. 2023: BiomX positive P1b/2a data 41 patients 43 patients Diabetic Foot Osteomyelitis Cystic Fibrosis Aug. 2024: Peer company reported May 2025: Peer company reported positive P2 Part
Slide 6: Shared Targets, Expanded Potential
Shared Targets, Expanded Potential: Clinical efficacy opens the door to potential additional Phase 2 studies across related infections Phase 2 Completed Diabetic Target: S. aureus Foot Infection & Osteomyelitis BX211 Diabetic Foot Osteomyelitis March 2025, Positive Phase 2 statistically Phase 2 Read
Slide 7: BiomX's Groundbreaking Phase 2 Results
BiomX's Groundbreaking Phase 2 Results Efficacy of phage therapy across indications Diabetic Foot Osteomyelitis (BX211): Cystic Fibrosis (BX004): On top of antibiotic SoC On top of antibiotic SoC -2.91 log10 CFU/g The 1st multi-center, double-blind, placebo- Demonstration of ability of phage to conv
Slide 8: BiomX Built on a Strong Foundation
BiomX—Built on a Strong Foundation: Backed by leaders in science, industry, and capital Strong Science & Scientific Founders Trusted by top biotech and healthcare investors Prof. Rotem Sorek Head of microbial genomics group at Weizmann Institute Phage genomics and CRISPR research Prof. Eran Elinav ≥
Slide 9: Diabetic Foot BX211
BX211 Diabetic Foot Infections & Diabetic Foot Osteomyelitis (DFI & DFO)
Slide 10: Disease Burden: DFI & DFO drive diabetic amputations
Disease Burden: DFI & DFO drive diabetic amputations, burdening the healthcare system DFI to DFO Staphylococcus aureus is Bacterial infection the most common bacteria spreading from soft present in DFI / DFO tissue to bone Superficial ulcer DFI DFO Standard of Care Moderate-to-severe DFI & DFO SoC:
Slide 11: Phase 2 Study Design: BX211
Phase 2 Study Design: Multicenter, double blind, placebo- controlled study to assess improvement of clinical outcomes Primary Endpoint: Percent area reduction of study ulcer through Week 13 Duration: 12 weeks of once weekly treatment Enrollment: BX211 IV in week 1, topical for 12 weeks Week 13 Week
Slide 12: Results Highlight: Phase 2 diabetic foot osteomyelitis
Results Highlight: Phase 2 diabetic foot osteomyelitis Statistically significant Safe and well-tolerated improvements in ulcer depth in patients with ulcers at bone depth Sustained and statistically significant PAR ulcer size Favorable trends reduction1 compared to placebo Separation from placebo
Slide 13: Efficacy (1): BX211 reduction in ulcer surface area
Efficacy (1): BX211 showed clinically relevant, statistically significant1, reduction in ulcer surface area Percent Area Reduction (PAR) from baseline of ulcer surface area (LS Mean ± SE)2 (See detailed data in next slide) P=0.046 P=0.052 >40% Group Placebo BX211 1. Not adjusted 2. Areas colored in
Slide 14: Efficacy (2): BX211 reduction in ulcer surface area
Efficacy (2): BX211 showed clinically relevant, statistically significant2, reduction in ulcer surface area Percent Area Reduction (PAR) from baseline of ulcer surface area (LS Mean ± SE)1 (Detailed data from previous slide) BX211 Placebo PAR at week: Difference (95% CI) P-value2 N (%) Mean (95% CI)
Slide 15: Efficacy (3): Patients with ulcers at bone depth
Efficacy (3): Patients with ulcers at bone depth1 displayed statistically significant2 better recovery in the BX211 group Change in tissue involvement of the ulcer for weeks 1 and 131 Depth Measurement Tissue3 Healed BX211 (N=13) Placebo (N=9) Dermis Below Dermis Week 1 Week 13 Week 1 Week 13 Bone 1
Slide 16: Cystic Fibrosis and NCFB
BX004 Cystic Fibrosis and NCFB
Slide 17: Cystic Fibrosis: Chronic pulmonary infections primary cause of death
Cystic Fibrosis: Chronic pulmonary infections and the inflammatory response are primary causes of death in CF Cystic Fibrosis Thickened Thick, sticky mucus traps bacteria and hinders Thick mucus promotes Mucus normal airway clearance, fostering chronic lung chronic bacteria infections, often driven
Slide 18: Phase 1b/2a Study Design
Phase 1b/2a Study Design: Multicentered, double blind, placebo- controlled study to assess safety, reduction of PsA burden and improvement in clinical outcomes Part 11 Part 2 Enrollment: BX004 7 days - Single 10 days of same ascending dose followed dose, twice daily 43 CF patients by multiple doses2
Slide 19: Results Highlight: Phase 1b/2a cystic fibrosis
Results Highlight: Phase 1b/2a cystic fibrosis (Part 1 and 2) Study drug was well-tolerated Reduction in bacterial load Culture conversion Clinical efficacy Part 1, at Day 15: 2.7 log₁₀ CFU/g Part 2, in the BX004 arm, 3 of 21 BX004 showed signals of treatment effect (represents (14.3%) patients conv
Slide 20: Efficacy (1): BX004 reduction in PsA levels
Efficacy (1): BX004 demonstrated greater reduction in PsA levels compared to placebo PART 1 (on top of antibiotic SoC): PART 2 (on top of antibiotic SoC, continuous subgroup): -2.91 log10 CFU/g Treatment Follow up Treatment Follow up Day CFU/g log change from Baseline: Mean (SE) CFU/g log change fro
Slide 21: Efficacy (2): BX004 culture conversion
Efficacy (2): BX004 showed greater conversion (bacterial culture turned negative) in treatment over placebo In the BX004 arm 3 out of 21 (14.3%) patients converted to sputum culture negative for P. aeruginosa after 10 days of treatment (2 already after 4 days)2. In the placebo arm 0 out of 10 (0%)2
Slide 22: Efficacy (3): BX004 clinical improvement after 10 days
Efficacy (3): BX004 shows meaningful clinical improvement after 10 days of treatment in multiple clinical readouts 1 ppFEV1 CFQR (respiratory) Treatment Follow up Treatment Follow up BX004 BX004 Clinical improvements Placebo Placebo were observed on both # objective & patient reported outcomes 5.67%
Slide 23: Phase 2b Study: Study design
Phase 2b Study: Study design International, multicenter, double blind, placebo-controlled study to assess reduction of PsA burden and improvement in clinical outcome Part 2b BX004 2 months of same dose, Enrollment: twice daily Objective: ~60 CF patients1 with chronic PsA infections 2 months 6 months
Slide 24: BiomX Regulatory Strategy
BiomX Regulatory Strategy P. aeruginosa (PsA) reduction improves patient outcomes, and ongoing real-world evidence (RWE) analysis may support approval based on this microbiology endpoint RWE - Non-interventional study Use of registry databases to support relevance of PsA reduction in the era of CFTR
Slide 25: NCFB: A promising next candidate
NCFB: A promising next candidate given its medical similarity to cystic fibrosis Non-Cystic Fibrosis Worse Clinical Symptoms and More Inpatient / Outpatient Encounters Associated with PsA Infections2 Bronchiectasis (NCFB) Inpatient Admissions Outpatient Admissions per Pt (1 yr) per Pt (1 yr) 2.6 PsA
Slide 26: Summary
Summary
Slide 27: Reputable Investors & Partners
Reputable Investors & ≥ $215 M Partners 3 Patent Raised Families ~$40M Non-Dilutive Robust Scientific Expertise 2 Phage Therapy ≥ 50% PhDs in Leadership Programs Strong 2 Phase 2 ≥ $4 B Addressable Manufacturing Studies Market World-wide Capabilities 27